B reast cancer is the most common cancer for women in the world and it is the second leading cause of cancer death among women according to the data of World Health Organization. Patients' prognosis and therapeutic response are highly variable due to the heterogeneity of breast cancer, so that personalized targeted therapy is urgently needed to improve the efficiency of disease control. For more individualized and precise treatment, breast cancer is divided into four subtypes, i.e., luminal A, luminal B, ERBB2+ and basal-like (triple negative), according to tumor cells' molecular and genetic information (1). Of the four subtypes, hormone receptor positive tumors (including luminal A and luminal B) tend to have better prognosis, while the basal-like tumors often have a poor prognosis. ERBB2+ subtype refers to human epidermal growth factor receptor 2 (HER2) positive tumors, which tend to be more aggressive and have a relatively poorer prognosis than the hormone receptor positive subgroups. Basal-like subtype seems to be worst in prognosis and therapy resistant (2-4).
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Structural imaging is commonly used to detect breast lesions and describe the anatomic features but it has been well known that functional abnormalities including metabolic changes emerge much earlier than the morphologic changes of breast cancer. As one of the molecular imaging modalities, positron emission tomography/ computed tomography (PET/CT), has greatly improved the sensitivity and specificity of diagnosis by providing both anatomical and metabolic information. In the last decade 18 
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PURPOSE
We aimed to quantitatively evaluate volumetric metabolic tumor burden including metabolic tumor volume and total lesion glycolysis in different molecular subtypes of breast cancer using 18 F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT).
METHODS
This study involved 99 female patients with pathologic diagnosis of primary breast cancer, who underwent 18 F-FDG PET/CT before any therapy. Patients were divided into subtypes of luminal A, luminal B, ERBB2+, and basal-like based on the immunohistochemistry results. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) before and after correction for lean body mass were achieved and compared. Correlations between metabolic tumor burden and Ki-67 were analyzed and diagnostic performances of volumetric metabolic parameters were evaluated.
RESULTS
TLG values were significantly different between each molecular subtype, while MTV values were not. Values of TLG were significantly reduced after normalizing for lean body mass in each subtype. Both of them showed correlations with Ki-67 and presented high diagnostic ability in identifying patients with basal-like breast cancer from the rest. TLGs before and after normalizing for the lean body mass had similar diagnostic performances in differentiating patients of basal-like subtype from the rest.
CONCLUSION
Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.
PET/CT has been widely used in clinical practice to characterize and stage tumors noninvasively. It is able to identify cancer in its early stage, reflect the glycolytic changes of tumors, and simultaneously evaluate the whole body's responses to the tumors in vivo. Standardized uptake value (SUV), as a semiquantitative index in PET/CT to demonstrate the uptake of glucose in tumors/normal tissues, has been popularly accepted by nuclear physicians in daily use but it remains questionable because of several reasons. First, the semiquantitative SUV max is a sensitive indicator of metabolic activity and tumor proliferation in breast cancer; however, it is the SUV on the highest image pixel, reflecting a single-pixel value of the maximum intensity of 18 F-FDG activity in the tumor, ignoring the extent of metabolic abnormality and changes in the distribution of a tracer within the whole tumor mass (5, 6) . Second, SUV is calculated based on the whole-body weight metric. Fat contributes to body weight without accumulating 18 F-FDG in the fasting state, leading to overestimated SUV in obese patients compared with normal or underweight patients (7) . Third, studies have reported that SUV could be influenced by many factors and SUV max is not reliable and recommendable because of its poor reproducibility (3%±11%) (8) (9) (10) . To overcome these controversies, researchers recommended the volume-based variables such as metabolic total volume (MTV) and total lesion glycolysis (TLG) to reflect the metabolic activities within the whole tumor mass; instead of the whole-body weight, the administered dose should be based on volume-based parameters that are corrected by the lean body mass (LBM) (11, 12) .
Studies have reported differences of SUV-based variables and metabolic tumor burden in breast cancer (2, 3, 13) . To our knowledge, few studies have addressed the changes and characteristics of metabolic tumor burden and LBM corrected quantitative volume-based parameters in different molecular subtypes of breast cancer. The purpose of this study was to retrospectively investigate the molecular subtypes of breast cancer with volumetric metabolic parameters on 18 F-FDG PET/CT, including MTV and TLG before (bodyweight TLG, TLG BW ) and after normalizing for LBM (TLG LBM ). Associations between the quantitative parameters and tumor biological characteristics of primary breast cancer were evaluated as well. The performances of SUV before and after normalizing for LBM were both assessed as well.
Methods
Patient selection
Ninety-nine cases of primary breast cancer between January 2015 to January 2016 in our institute and hospital were reviewed. All of the patients were pathologically diagnosed as primary breast cancer by core needle biopsy and immunohistochemistry (IHC) test was performed consecutively. The patients had the examination of 18 F-FDG PET/CT before operation and/or other therapeutic interventions. Each patient was required to sign the informed consent form before the examination. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee.
Molecular imaging acquisition and analysis
All F-FDG (3.7 MBq/kg). CT scanning was performed with the following parameters: current 120-160 mA, voltage 120 kV, slice thickness 5 mm or 3.75 mm, and reconstruction interval 5 mm or 3.75 mm. Afterwards, PET images were acquired in the three-dimensional mode with 2 min per bed position without holding breath from head to the midthigh. The CT-based attenuation-corrected PET images were reconstructed using an iterative algorithm, with 128×128 matrix and 3.75 mm reconstruction slice thickness. All images, including CT, PET, and fusion images after partial volume effect correction, were reviewed by two nuclear medicine physicians with 7 and 10 years of experience in nuclear diagnosis, respectively. The masses in breasts were selected as the region of interest (ROI) and the largest lesion was chosen in patients with multifocal or multicentric foci. The average diameter (the average value of maximum and minimum diameter) of ROI was measured. Volume-based parameters including MTV, SUV max , SUV mean (mean SUV), SUL peak (peak SUV normalized for LBM) and SUL mean (mean SUV normalized for LBM) were obtained using PET VCAR, semiquantitative software that is imbedded in GE workstation (estimated threshold for discrimination of tumors was chosen as equaling to or more than 42% of SUV max ). TLG BW (TLG BW =MTV× SUV mean ) and TLG LBM (TLG LBM =MTV× SUL mean ) were calculated based on above formulas, respectively. The performances of SUV max and SUL peak were both assessed as references. Metastasis including ipsilateral or contralateral axillary and other lymph nodes and distant metastases were observed as well.
Categorization of molecular subtypes
According to the molecular characteristics-based classification in the 12 th International Breast Cancer Conference in 2011, all patients were divided into four subtypes: 1) luminal A: hormone receptor ER and/or PR positive (ER or PR expression >1%), HER2 negative ("HER2 0" or "HER2+"), and low expression of Ki-67 (<14%); 2) luminal B: a) hormone receptor ER and/or PR positive, HER2/neu positive ("HER2+++", or "HER2++" but "FISH+"), b) hormone receptor ER and/ or PR positive, HER2/neu negative and high expression of Ki-67 (≥14%); 3) ERBB2 + : hormone receptors negative, HER2/neu positive; and 4) Basal-like (triple negative): hormone receptors and HER2 negative. Biologic prognostic parameters, including proliferation rate (Ki-67) and the expression level of p53, were obtained as well.
Statistical analysis
The software package SPSS 16.0 (SPSS Inc.) was used for statistical analysis and graphics. The inter-rater agreement rate was evaluated using the interclass correlation coefficient (ICC) on acquisition of data of all patients, with raters as independent variables. TLG before and after correction for LBM were compared using the pairwise t test. Group differences of volume-based parameters in each molecular subtype were compared using analysis of variance
Main points
• Different features of metabolic tumor volume and total lesion glycolysis were found with high heterogeneity in molecular subtypes of breast cancer.
• Metabolic tumor burden could comprehensively reflect the metabolic differences of molecular subtypes of breast cancer.
• Total lesion glycolysis could be used to help differentiate patients in basal-like subtype of breast cancer. 
Results
All subjects in this study were female with breast cancer in single breast, with age ranging from 29 to 80 years (median, 52 years; mean, 52.0±9.9 years). Most patients (n=72, 72.7%) were between 40 and 60 years; number of patients younger than 40 years and older than 60 years were 11 (11.1%) and 16 (16.2%), respectively. Among the patients, 4 (4.3%) had other malignant cancers historically, such as cancer in the contralateral breast (n=1), colon (n=1), cervix (n=1), and stomach (n=1). According to the IHC results, luminal A, luminal B, ERBB2+, and basal-like accounted for 27.3%, 34.7%, 19.2%, and 19.2% of cases, respectively (Table) . Metastasis of lymph nodes was found in 80.8% (n=80) of patients and distant metastases were observed in 23.2% (n=23) of patients.
The inter-rater agreement analysis showed high reliability (ICC, 0.98; 95% CI, 0.81-0.94) for the measurement of MTV and TLG. The volume-based data showed that MTV differed in each molecular subgroup with large variability, but did not reach statistical significance, whereas the average size of the tumors was significantly different between the four subgroups (χ 2 =1.76, P = 0.175) (Table) . A high correlation was found between MTV and size measurement (r=0.74, P < 0.001). Furthermore, pairwise comparisons of TLG BW (145.88±245.80) and TLG LBM (100.88±165.23) showed that the TLG values were significantly reduced after normalizing for LBM in all subjects (Z=-8.64, P < 0.001), as well as in each subtype (P = 0.001-0.006) (Fig. 1) . Values of TLG before and after normalizing for LBM were both significantly different within the four molecular subtypes (Z=-2.73, P = 0.007 for TLG BW ; Z=-2.80, P = 0.006 for TLG LBM ) (Table) . After normalizing for LBM, the SUL peak was lower than the SUV max and it was significantly different between each subgroup (Fig.  2, Table) . Significant group and pairwise differences were shown in TLG BW , TLG LBM , SUV max and SUL peak between the luminal A and basal-like subgroups and between ERBB2+ and basal-like subgroups (details in the Table) . The patients with lymph node involvement had significantly higher TLG BW (166.56±265.14 vs. 58.80±102.14, Z=-3.00, P = 0.003) and TLG LBM (115.32±178.12 vs. 40.06±67.53, Z=-2.95, P = 0.003) than those without lymph node metastases, whereas no significant difference of either TLG BW or TLG LBM was found between patients with and without distant organ metastases (Fig.  3) . Correlation was found between TLG BW and the expression level of Ki-67 (r=0.26, P = 0.009) and between TLG LBM and Ki-67 after normalizing for LBM (r=0.27, P = 0.007), but without significant advantage in TLG BW or TLG LBM . However, neither TLG BW nor TLG LBM was associated with the expression level of p53. As for the diagnosing ability, the values of TLG BW and TLG LBM had similar performance in differentiating patients of basal-like subtype from those in non-basal-like subtypes with the AUC of 0.697 for TLG LBM (95% CI, 0.564-0.831) and 0.691 for TLG BW (95% CI, 0.556-0.827) (Fig. 4) . Using the cutoff values of TLG LBM =101.46 and TLG BW =142.93, the sensitivity, specificity and accuracy values were 52.6%, 78.8%, 73.7%, and 52.6%, 76.3%, 71.7%, respectively. The sensitivity, specificity, and accuracy of SUV max were 73.7%, 70.0%, and 69.7%, respectively, when using the cutoff value of SUV max =11.6, whereas the sensitivity, specificity and accuracy of SUL peak were 73.7%, 67.5%, and 68.7%, respectively, when using the cutoff value of SUL peak =6. 16 .
Discussion
Studies have demonstrated that 18 F-FDG PET/CT could be utilized to measure the metabolic abnormalities in patients with breast cancer (13) . Our study made a retrospective analysis on metabolic tumor burden in IHC-defined molecular subtypes of primary breast cancer. They displayed different features of metabolic tumor volume and total lesion glycolysis with high heterogeneity. Among these subtypes, the basal-like group showed youngest age at diagnosis, largest MTV, and highest TLG. Glucose uptake, which is a hallmark of cancers, increases with malignancy through up-regulation of membrane glucose transporters and improving the activity of hexokinase. It is usually evaluated on FDG-PET by calculating SUV in the tumor and SUV max is the most commonly used parameter in clinical trials. However, tumor metabolic burden in terms of MTV and TLG have been reported to be capable of comprehensively reflecting glucose uptake within the whole tumor rather than a single-pixel value of 18 F-FDG activity (SUV max ). They were adopted as the optimal parameters for therapeutic evaluation by PET Response Criteria in Solid Tumors (PERCIST) (14) . Our data showed that the volume-based MTV could serve as a variable in the evaluation of initial breast cancer although the difference of MTV in each subtype did not reach statistical significance, with the lowest values of mean and median MTV in the subgroup of ERBB2+. MTV is able to reflect the metabolic volume, which is the FDG-avid volume in the tumor, rather than the size of the mass. It correlates with the size of the mass but provides more accurate measurement than the maximum or minimum diameters, especially for lesions with non-FDG-uptake necrosis inside. Obesity is becoming an increasingly frequent problem in public health worldwide. Based on numerous meta-analyses, strong evidence supported the association of obesity with 11 types of cancer, including breast cancer, especially postmenopausal breast cancer (15, 16) . Furthermore, being overweight was reported to increase risk of basal-like breast cancer and decrease risk of luminal A and B subtypes in premenopausal women (17) . This fact makes it more prominent and important to apply LBM normalized FDG uptake values to avoid the adiposity-induced bias in evaluating the metabolic changes in breast cancer. SUL, the SUV normalized for LBM, has been recognized as the optimal parameter instead of SUV by PERCIST for therapeutic evaluation. In this study, SUL peak showed comparable performance with SUV max , without significant advantage in the initial evaluation of breast cancer. Is TLG after correcting for LBM more reliable and feasible for clinical trials of breast cancer than non-corrected TLG? Are they also suitable for initial assessment of breast cancer? Our study showed that both TLG BW and TLG LBM could be used in the initial evaluation of metabolic changes and tumor glycolytic activity in different molecular subtypes of primary breast cancer other than reflecting response to therapy.
Ki-67 index is a proliferation-associated antigen and has been accepted as a reliable marker to measure tumor cell proliferation and prognosis (5) . Studies have demonstrated that there was a significant correlation between 18 F-FDG uptake and Ki-67 (18) (19) (20) (21) . Our data confirmed this positive relationship between Ki-67 and TLG, indicating that TLG might be correlated with the prognosis of breast cancer. It is well known that basal-like breast cancer is associated with aggressive behavioral features. In our study, people in this group demonstrated younger age at onset, larger size/volume, higher proliferation, and worst prognosis than the other subgroups, indicating the prominent importance of making an accurate differentiating diagnosis. Our data confirmed that both TLG BW and TLG LBM had high ability to distinguish patients of basal-like from those of non-basal-like. They had similar performance, but TLG LBM showed a slight superiority to TLG BW .
There are several limitations to this study. It was a retrospective cohort so that it had several unavoidable biases. A larger sample of patients with breast cancer needs to be included for a better understanding of the molecular imaging features in different IHC-based subtypes of breast cancer. In addition, therapeutic evaluation with the volume-based parameters should be added in further studies. In conclusion, according to our data, the volumetric variables including MTV and TLG both showed good performances to reflect and evaluate metabolic changes and tumor glycolytic activity in different molecular subtypes of primary breast cancer. After normalizing for LNB, TLG can provide more accurate and reliable evaluation of the metabolic changes of breast cancer than those parameters based on body weight. In addition, TLG could serve as a tool to help differentiate patients with the basal-like subtype from the other subtypes of breast cancer. The receiver operating characteristic curves of total lesion glycolysis before (TLG_BW) and after (TLG_LBM) normalizing for lean body mass to identify patients in the basal-like subtype.
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